City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
Click here to login to Secure Web Site   (authorized users only)  
  
Search results:  423  Clinical trial(s) found  (Page 1 of 17 )
Results per page: 25 50 100 All 1-25 Trials Jump to page:

The following studies are available for :
COH Protocol Number: 18380

Principal Investigator: Jeannine Mccune, PharmD
Sponsor: Institutional

Title:  Pilot Study to Evaluate Substances in Sweat, Saliva, and Blood

COH Protocol Number: 18376 ClinicalTrials.gov Number: NCT03640481

Principal Investigator: Amandeep Salhotra, MD
Sponsor: Industrial

Title:  A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease (cGVHD) After at Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)

COH Protocol Number: 18361

Principal Investigator: Brooke Crawford, MD
Sponsor: Institutional

Title:  Robot Assistance for CT Guided Needle Placement

COH Protocol Number: 18358

Principal Investigator: Jeannine Mccune, PharmD
Sponsor: Institutional

Title:  Blood Samples to Identify Biomarkers for Post-transplant Cyclophosphamide

COH Protocol Number: 18334 ClinicalTrials.gov Number: NCT03126630

Principal Investigator: Marianna Koczywas, MD
Sponsor: NCI Approved External Peer Review

Title:  PHII-175 NCI# 10107 Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and MK-3475 (Pembrolizumab) Compared to MK-3475 (Pembrolizumab) Alone for Mesothelin-Positive Malignant Pleural Mesothelioma

COH Protocol Number: 18329

Principal Investigator: Joseph Chao, MD
Sponsor: Industrial

Title:  A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (anti-LAG-3) plus Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First-Line Treatment in Patients with Gastric or Gastroesophageal Junction Adenocarcinoma

COH Protocol Number: 18328 ClinicalTrials.gov Number: NCT03597581

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Phase 1 Study of RGX-202-01, A Small Molecule Inhibitor of the Creatine Transporter, SLC6a8, with or without FOLFIRI in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts

COH Protocol Number: 18317

Principal Investigator: Christiane Querfeld, MD, PhD
Sponsor: Industrial

Title:  SOLAR: A Phase 2 Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype

COH Protocol Number: 18311

Principal Investigator: Marwan Fakih, MD
Sponsor: Institutional

Title:  Expanded Access Protocol for HS, RXDX-105 for the Treatment of a Patient with Non-Small Cell Lung Cancer (NSCLC) Harboring a CCDCD6-RET Gene Fusion

COH Protocol Number: 18309 ClinicalTrials.gov Number: NCT03375320

Principal Investigator: Daneng Li, MD
Sponsor: Cooperative Group

Title:  Alliance A021602: Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors after Progression on Everolimus (CABINET)

COH Protocol Number: 18306

Principal Investigator: Victoria Seewaldt, MD
Sponsor: Institutional

Title:  Food Deserts and Insulin Resistance

COH Protocol Number: 18305

Principal Investigator: Anne Reb, RN, PhD
Sponsor: Institutional

Title:  Conquer Fear SUPPORT: A Psychosocial Intervention in Patients with Advanced Cancer

COH Protocol Number: 18295

Principal Investigator: Veronica Jones, MD
Sponsor: Institutional

Title:  Predictors of Chemoresistance in Locally Advanced Luminal B Breast Cancer

COH Protocol Number: 18294

Principal Investigator: Arya Amini, MD
Sponsor: Institutional

Title:  Geriatric Assessment and Quality of Life in Older Adults Undergoing Chemoradiation for Head and Neck Cancer and Their Family Caregivers

COH Protocol Number: 18289 ClinicalTrials.gov Number: NCT03504397

Principal Investigator: Joseph Chao, MD
Sponsor: Industrial

Title:  A Phase 3, Global, Multi-Center, Double- Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

COH Protocol Number: 18282 ClinicalTrials.gov Number: NCT03669718

Principal Investigator: Erminia Massarelli, MD, PhD
Sponsor: Industrial

Title:  A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab With ISA101b in the Treatment of Subjects With HPV16-Positive Platin-Resistant Oropharyngeal Cancer (OPC)

COH Protocol Number: 18280 ClinicalTrials.gov Number: NCT03600883

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Phase 1, First-in-Human, Open-label Study Evaluating the Safety,Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With a Specific KRAS Mutation

COH Protocol Number: 18274 ClinicalTrials.gov Number: NCT03597295

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Phase 2 Study of INCMGA00012 in Participants with Squamous Carcinoma of the Anal Canal who have Progressed Following Platinum-Based Chemotherapy

COH Protocol Number: 18269 ClinicalTrials.gov Number: NCT03327857

Principal Investigator: Haris Ali, MD
Sponsor: Industrial

Title:  A Phase I Study of Neihulizumab (AbGn-168H) in Patients with Steroid-refractory Acute Graft-versus-host Disease (sr-aGvHD)

COH Protocol Number: 18265 ClinicalTrials.gov Number: NCT03454451

Principal Investigator: Sumanta Pal, MD
Sponsor: Industrial

Title:  A Phase 1/1b Multicenter Study to Evaluate the Humanized Anti-CD73 Antibody, CPI-006, as a Single Agent, in Combination with CPI-444, and in Combination with Pembrolizumab in Adult Subjects with Advanced Cancers

COH Protocol Number: 18263 ClinicalTrials.gov Number: NCT03541369

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

COH Protocol Number: 18261 ClinicalTrials.gov Number: NCT03418532

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  A Phase 1b/2, Single-arm, Open-label, Multi-center Study of MP0250 in Combination with Osimertinib in Patients with EGFR-mutated Non-Squamous Non-small Cell Lung Cancer (NSCLC) Treated with Osimertinib

COH Protocol Number: 18260 ClinicalTrials.gov Number: NCT03499353

Principal Investigator: Yuan Yuan, MD, PhD
Sponsor: Industrial

Title:  A Phase 2, Non-randomized, Open Label, Single Arm, Multi-center Study Of Talazoparib For Neoadjuvant Treatment Of Germline Brca1/2 Mutation Patients With Early Triple-negative Breast Cancer

COH Protocol Number: 18254 ClinicalTrials.gov Number: NCT03671018

Principal Investigator: L. elizabeth Budde, MD, PhD
Sponsor: Industrial

Title:  An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluation the Safety, Tolerability, Pharmacokinetics and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with Polatuzumab Vedotin in Patients with B-Cell Non-Hodgkin Lymphoma

COH Protocol Number: 18248 ClinicalTrials.gov Number: NCT03560531

Principal Investigator: Joanne Mortimer, MD
Sponsor: Industrial

Title:  A Phase I Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Zn-C5 Alone and in Combination with Palbociclib in Subjects with Previously Treated Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer

 
Results per page: 25 50 100 All 1-25 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.